+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 50Years
All Genders
Healthy Volunteers
ID07565090

Randomized, Observer-blind, Placebo-controlled Study to Evaluate rVSV94G-SUDV-GP Vaccine Safety and Immune Response in Healthy Adults

Led by International AIDS Vaccine Initiative · Updated on 2026-09-21

112

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase 1 clinical trial to evaluate the safety and immune response of the rVSV94G-SUDV-GP vaccine designed to prevent Sudan Virus Disease in healthy adults aged 18 to 50 years. This study uses a randomized, observer-blind, placebo-controlled, dose-escalation design to carefully assess different dose levels of the vaccine. The trial is led by the International AIDS Vaccine Initiative and involves close monitoring for safety and vaccine response.

CONDITIONS

Brief Title

A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health

Research Team

J

Johannes Beeslaar, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here